secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122770
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024
--------------------------------------------------------------------------------

- Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.
- Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.
- Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.
- ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.
- Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/0000950170-24-122770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/qttb-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer